These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 17039505

  • 21. Understanding the drug-eluting stent trials.
    Coolong A, Kuntz RE.
    Am J Cardiol; 2007 Sep 03; 100(5A):17K-24K. PubMed ID: 17719349
    [Abstract] [Full Text] [Related]

  • 22. Sirolimus-eluting stents for the treatment of atherosclerotic ostial lesions.
    Aziz S, Ramsdale DR.
    J Invasive Cardiol; 2005 Jan 03; 17(1):13. PubMed ID: 15640532
    [No Abstract] [Full Text] [Related]

  • 23. The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured?
    Beyar R, Roguin A.
    Eur Heart J; 2001 Nov 03; 22(22):2054-7. PubMed ID: 11686663
    [No Abstract] [Full Text] [Related]

  • 24. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A, LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators.
    J Am Coll Cardiol; 2009 May 12; 53(19):1760-8. PubMed ID: 19422982
    [Abstract] [Full Text] [Related]

  • 25. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F.
    J Am Coll Cardiol; 2009 May 12; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract] [Full Text] [Related]

  • 26. Peeling-off labels mounting evidence for benefit of drug-eluting stents with off-label use.
    Büttner HJ, Neumann FJ.
    J Am Coll Cardiol; 2007 Nov 20; 50(21):2037-8. PubMed ID: 18021869
    [No Abstract] [Full Text] [Related]

  • 27. Drug-eluting stents for the prevention of restenosis: Standing the test of time.
    Carter AJ.
    Catheter Cardiovasc Interv; 2002 Sep 20; 57(1):69-71. PubMed ID: 12203932
    [No Abstract] [Full Text] [Related]

  • 28. Drug-eluting stents.
    Med Lett Drugs Ther; 2003 Mar 17; 45(1152):23-4. PubMed ID: 12637894
    [No Abstract] [Full Text] [Related]

  • 29. Contemporary treatment of coronary bifurcations with DES: part I.
    Colombo A.
    J Interv Cardiol; 2005 Oct 17; 18(5):351-4. PubMed ID: 16202109
    [No Abstract] [Full Text] [Related]

  • 30. Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents.
    Corbett SJ, Babic R, Cosgrave J, Sangiorgi GM, Colombo A.
    Cardiovasc Revasc Med; 2006 Oct 17; 7(3):159-64. PubMed ID: 16945823
    [Abstract] [Full Text] [Related]

  • 31. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ, ZEST-AMI Investigators.
    Am J Cardiol; 2009 Nov 15; 104(10):1370-6. PubMed ID: 19892052
    [Abstract] [Full Text] [Related]

  • 32. New treatment for clogged coronary arteries.
    Mayo Clin Health Lett; 2002 Dec 15; 20(12):4. PubMed ID: 12526107
    [No Abstract] [Full Text] [Related]

  • 33. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O, Lagerqvist B, Carlsson J, Lindbäck J, Stenestrand U, James SK.
    J Am Coll Cardiol; 2009 May 05; 53(18):1660-7. PubMed ID: 19406341
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C, Barbagallo R, Capodanno D, di Matteo S, Colombo GL, Recchia M, Ciriminna S, Sicilian DES Registry Investigators.
    J Cardiovasc Med (Hagerstown); 2009 Apr 05; 10(4):322-9. PubMed ID: 19430343
    [Abstract] [Full Text] [Related]

  • 35. [Drug-eluting or bare-metal stents in interventional cardiology. Theory and practice].
    Er F, Erdmann E.
    Med Klin (Munich); 2007 Jan 15; 102(1):30-2. PubMed ID: 17221349
    [Abstract] [Full Text] [Related]

  • 36. Imminent extinction of brachy(saurus)therapy for the treatment of in-stent restenosis.
    Moliterno DJ.
    Catheter Cardiovasc Interv; 2006 Sep 15; 68(3):349-51. PubMed ID: 16894576
    [No Abstract] [Full Text] [Related]

  • 37. Editorial comment: which is the preferred drug-eluting stent?
    Brodie BR.
    J Interv Cardiol; 2006 Feb 15; 19(1):39-42. PubMed ID: 16483338
    [No Abstract] [Full Text] [Related]

  • 38. Is the end of restenosis the beginning of a new era?
    Moses JW.
    Ital Heart J; 2004 Feb 15; 5(2):81-4. PubMed ID: 15086136
    [No Abstract] [Full Text] [Related]

  • 39. [Drug-eluting stents in coronary arteries. The risk of restenosis is drastically reduced].
    Tornvall P.
    Lakartidningen; 2004 Dec 23; 101(51-52):4175. PubMed ID: 15658586
    [No Abstract] [Full Text] [Related]

  • 40. Bringing reality to drug-eluting stents.
    Faxon DP.
    Circulation; 2004 Jan 20; 109(2):140-2. PubMed ID: 14734500
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.